Haukeland universitetssjukehus is the first hospital in Norway to offer the innovative radiopharmaceutical, Lutetium-177-dotatate to patients with neuroendocrine tumours.
Previously the Norwegian patients had to travel to Sweden for the same treatment. The university hospitals Oslo universitetssykehus, St. Olavs hospital, Trondheim University Hospital and Tromsø University Hospital will soon follow Haukeland.
Share
